RPG Life Sciences Ltd (RPGLIFE) is currently trading at 2,798.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

RPG Life Sciences is a research-focused pharmaceutical company engaged in the development and marketing of formulations and APIs in both domestic and international markets. The company displayed a modest revenue growth of 4.0% in the 9M FY26 compared to the same period last year, although profit margins contracted due to increased expenditures. RPG Life Sciences is actively pursuing strategic capacity expansions and modernization of its manufacturing facilities, backed by a capex of ₹140 crore, to support its growth objectives. The company leverages a diversified product portfolio catering across several therapeutic segments like nephrology, oncology, cardiology, and more, with strong emphasis on chronic and specialty therapies. With zero debt and a reinforced balance sheet, the company secured a strong credit rating reaffirmation from ICRA, indicating robust financial health and sustainable growth.

Over the past 52 weeks, RPG Life Sciences Ltd has traded between a low of ₹1,731.25 and a high of ₹3,080.90. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

RPG Life Sciences Ltd has a market capitalization of approximately 4,640.19. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

RPG Life Sciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 38.78 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 4,640.19 Cr, RPG Life Sciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

RPG Life Sciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of RPG Life Sciences Ltd is 38.78. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The transfer was completed and became effective on August 15, 2026, according to the company’s letter to NSE and BSE.

Revenue from operations was ₹195.7 crore in Q1FY27, up from ₹168.9 crore in Q1FY26, a year-on-year increase of 15.8%.

Revenue from operations rose to ₹195.7 crore in Q1FY27, up from ₹168.9 crore in Q1FY26.

Paste the full source article text here (or share a link plus the text). Without the text, I cannot extract facts or numbers reliably.